EA201790696A1 - Способы и композиции для диагностики и прогнозирования повреждения почек и почечной недостаточности - Google Patents

Способы и композиции для диагностики и прогнозирования повреждения почек и почечной недостаточности

Info

Publication number
EA201790696A1
EA201790696A1 EA201790696A EA201790696A EA201790696A1 EA 201790696 A1 EA201790696 A1 EA 201790696A1 EA 201790696 A EA201790696 A EA 201790696A EA 201790696 A EA201790696 A EA 201790696A EA 201790696 A1 EA201790696 A1 EA 201790696A1
Authority
EA
Eurasian Patent Office
Prior art keywords
kidney damage
compositions
methods
prediction
diagnosis
Prior art date
Application number
EA201790696A
Other languages
English (en)
Inventor
Джозеф Андерберг
Пол Макферсон
Джефф Грей
Кевин Накамура
Джеймс Патрик Кампф
Томас Кван
Original Assignee
Астьют Медикал, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Астьют Медикал, Инк. filed Critical Астьют Медикал, Инк.
Publication of EA201790696A1 publication Critical patent/EA201790696A1/ru

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/521—Chemokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Настоящее изобретение относится к способам и композициям для мониторинга, диагностики, прогнозирования и определения схем лечения у субъектов, страдающих или предположительно страдающих повреждением почек. В частности, настоящее изобретение относится к применению анализов, обеспечивающих детекцию одного или более из содержащего С-С мотив хемокина 16, содержащего С-С мотив хемокина 14 и рецепторной тирозинкиназы UFO, в качестве диагностических и прогностических биомаркерных анализов при повреждениях почек.
EA201790696A 2014-10-20 2015-10-20 Способы и композиции для диагностики и прогнозирования повреждения почек и почечной недостаточности EA201790696A1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462066313P 2014-10-20 2014-10-20
US201462066310P 2014-10-20 2014-10-20
US201462066316P 2014-10-20 2014-10-20
PCT/US2015/056462 WO2016064877A2 (en) 2014-10-20 2015-10-20 Methods and compositions for diagnosis and prognosis of renal injury and renal failure

Publications (1)

Publication Number Publication Date
EA201790696A1 true EA201790696A1 (ru) 2017-10-31

Family

ID=55761743

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201790696A EA201790696A1 (ru) 2014-10-20 2015-10-20 Способы и композиции для диагностики и прогнозирования повреждения почек и почечной недостаточности

Country Status (13)

Country Link
US (2) US11333671B2 (ru)
EP (2) EP3210018B1 (ru)
JP (4) JP6792553B2 (ru)
KR (1) KR102431003B1 (ru)
CN (2) CN110702921B (ru)
AU (2) AU2015336069B2 (ru)
BR (1) BR112017008218A2 (ru)
CA (1) CA2965153C (ru)
EA (1) EA201790696A1 (ru)
ES (1) ES2907551T3 (ru)
MX (1) MX2017005126A (ru)
PT (1) PT3210018T (ru)
WO (1) WO2016064877A2 (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201790696A1 (ru) 2014-10-20 2017-10-31 Астьют Медикал, Инк. Способы и композиции для диагностики и прогнозирования повреждения почек и почечной недостаточности
WO2018132702A1 (en) * 2017-01-12 2018-07-19 Astute Medical, Inc. Methods and compositions for evaluation and treatment of renal injury and renal failure based on c-c motif chemokine ligand 14 measurement
EP3577458A4 (en) 2017-02-06 2021-04-07 Astute Medical, Inc. METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PREDICTION OF RENAL LESION AND RENAL INSUFFICIENCY
US11891439B2 (en) 2017-12-28 2024-02-06 Astute Medical, Inc. Antibodies and assays for CCL14
JP7221985B2 (ja) * 2018-04-02 2023-02-14 ポトレロ メディカル，インコーポレイテッド 体液の排出および分析、並びに健康の評価のためのシステム
CN114207436A (zh) * 2019-05-24 2022-03-18 机敏医药股份有限公司 基于c-c基序趋化因子配体14测量而评估和治疗肾损伤的方法
GB2596142B (en) * 2020-06-19 2023-11-29 Secr Defence Methods and associated uses, kits and systems for assessing sepsis

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5939272A (en) 1989-01-10 1999-08-17 Biosite Diagnostics Incorporated Non-competitive threshold ligand-receptor assays
US5028535A (en) 1989-01-10 1991-07-02 Biosite Diagnostics, Inc. Threshold ligand-receptor assay
US5922615A (en) 1990-03-12 1999-07-13 Biosite Diagnostics Incorporated Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network
CA2072758A1 (en) 1990-09-14 1992-03-15 Kenneth Francis Buechler Antibodies to complexes of ligand receptors and ligands and their utility in ligand-receptor assays
US5955377A (en) 1991-02-11 1999-09-21 Biostar, Inc. Methods and kits for the amplification of thin film based assays
CA2107894C (en) 1991-04-10 2003-10-14 Kenneth F. Buechler Crosstalk inhibitors and their uses
ES2150915T3 (es) 1991-04-12 2000-12-16 Biosite Diagnostics Inc Nuevos conjugados y dosificados destinados para la deteccion simultanea de ligandos multiples.
US5885527A (en) 1992-05-21 1999-03-23 Biosite Diagnostics, Inc. Diagnostic devices and apparatus for the controlled movement of reagents without membrances
US6143576A (en) 1992-05-21 2000-11-07 Biosite Diagnostics, Inc. Non-porous diagnostic devices for the controlled movement of reagents
US5494829A (en) 1992-07-31 1996-02-27 Biostar, Inc. Devices and methods for detection of an analyte based upon light interference
US5824799A (en) 1993-09-24 1998-10-20 Biosite Diagnostics Incorporated Hybrid phthalocyanine derivatives and their uses
US6811773B1 (en) * 1993-12-22 2004-11-02 Human Genome Sciences, Inc. Human monocyte colony inhibitory factor (M-CIF) polypeptides
US6113855A (en) 1996-11-15 2000-09-05 Biosite Diagnostics, Inc. Devices comprising multiple capillarity inducing surfaces
US5947124A (en) 1997-03-11 1999-09-07 Biosite Diagnostics Incorporated Diagnostic for determining the time of a heart attack
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
US20030157573A1 (en) 2002-02-12 2003-08-21 Orna Mor Use of Axl receptor for diagnosis and treatment of renal disease
US20120064089A1 (en) * 2002-11-15 2012-03-15 Morehouse School Of Medicine Anti-cxcl16 and anti-cxcr6 antibodies for the prevention and treatment of cancer and cancer cell migration
CA2614935A1 (en) 2005-07-21 2007-02-01 The Johns Hopkins University Methods of detecting and treating acute kidney injury
US20070128174A1 (en) 2005-09-21 2007-06-07 Kleinsek Donald A Methods and compositions for organ and tissue functionality
US20110059537A1 (en) 2007-09-20 2011-03-10 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Method for estimating risk of acute kidney injury
US20090226435A1 (en) 2008-03-08 2009-09-10 Sanjay Khare Engineered fusion molecules immunotherapy in cancer and inflammatory diseases
NZ619918A (en) * 2008-10-21 2015-04-24 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CA2770259A1 (en) * 2009-08-07 2011-02-10 Rules-Based Medicine, Inc. Methods and devices for detecting obstructive uropathy and associated disorders
NZ619883A (en) 2009-09-21 2014-11-28 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ600160A (en) * 2009-11-07 2014-05-30 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
JP2013510322A (ja) * 2009-11-07 2013-03-21 アスチュート メディカル，インコーポレイテッド 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
CN104698161A (zh) 2009-12-20 2015-06-10 阿斯图特医药公司 用于肾损伤和肾衰竭的诊断及预后的方法和组合物
US20120156701A1 (en) * 2009-12-20 2012-06-21 Joseph Anderberg Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN102791885B (zh) * 2010-02-05 2015-09-09 阿斯图特医药公司 用于肾损伤和肾衰竭的诊断及预后的方法和组合物
WO2011162820A1 (en) * 2010-06-23 2011-12-29 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP3339859A1 (en) * 2010-06-23 2018-06-27 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
AU2011269775B2 (en) * 2010-06-23 2015-01-15 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
UY33492A (es) * 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
WO2012136548A1 (en) 2011-04-04 2012-10-11 Universiteit Gent Biomarkers for acute kidney injury
ES2721907T3 (es) * 2011-08-26 2019-08-06 Astute Medical Inc Métodos y composiciones para el diagnóstico y pronóstico de lesión renal e insuficiencia renal
WO2013086359A1 (en) * 2011-12-08 2013-06-13 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2013096740A1 (en) * 2011-12-21 2013-06-27 Alere San Diego Inc. Methods and compositions for assigning likelihood of chronic kidney disease progression
US20160003850A1 (en) 2013-02-26 2016-01-07 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EA201790696A1 (ru) 2014-10-20 2017-10-31 Астьют Медикал, Инк. Способы и композиции для диагностики и прогнозирования повреждения почек и почечной недостаточности

Also Published As

Publication number Publication date
BR112017008218A2 (pt) 2018-01-09
CN107003301B (zh) 2019-11-01
JP2023052587A (ja) 2023-04-11
JP2021039112A (ja) 2021-03-11
ES2907551T3 (es) 2022-04-25
KR102431003B1 (ko) 2022-08-09
JP7002623B2 (ja) 2022-02-10
EP3210018A4 (en) 2018-06-20
CN110702921A (zh) 2020-01-17
JP2022046669A (ja) 2022-03-23
MX2017005126A (es) 2017-09-15
EP3210018A2 (en) 2017-08-30
JP7217796B2 (ja) 2023-02-03
CA2965153A1 (en) 2016-04-28
US20180209990A1 (en) 2018-07-26
JP6792553B2 (ja) 2020-11-25
CN110702921B (zh) 2024-02-06
US11333671B2 (en) 2022-05-17
EP3210018B1 (en) 2021-07-28
JP2017533427A (ja) 2017-11-09
WO2016064877A2 (en) 2016-04-28
CN107003301A (zh) 2017-08-01
US20220236286A1 (en) 2022-07-28
PT3210018T (pt) 2021-10-04
AU2015336069A1 (en) 2017-05-25
AU2022201130A1 (en) 2022-03-17
AU2015336069B2 (en) 2021-11-25
KR20170084102A (ko) 2017-07-19
EP3968022A1 (en) 2022-03-16
CA2965153C (en) 2023-10-24
WO2016064877A3 (en) 2016-09-09

Similar Documents

Publication Publication Date Title
EA201790696A1 (ru) Способы и композиции для диагностики и прогнозирования повреждения почек и почечной недостаточности
EA201290711A1 (ru) Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности
MX2018012580A (es) Métodos y kits para el diagnóstico y la estratificación de riesgo en pacientes con isquemia.
MX367046B (es) Marcadores especificos de via para diagnosticar sindrome del intestino irritable.
EA201290629A1 (ru) Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности
MX2019008260A (es) Metodos y composiciones para la evaluacion y tratamiento de lesion renal e insuficiencia renal con base en la medicion del ligando 14 de quimiocina de la porcion c-c.
EA201290056A1 (ru) Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности
EP3734280A3 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP2767833A3 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
BR112016016101A2 (pt) Métodos para determinar o estado do distúrbio inflamatório, para monitorar a progressão de uma doença inflamatória ou monitorar a eficácia de um tratamento, kit, e, uso da determinação da presença, ou do nível, de tesnacina-c citrulinada e/ou um ou mais fragmentos de tesnacina-c citrulinada e/ou de autoanticorpos com especificidade para os mesmos
MX2021012347A (es) Composiciones, metodos y kits para el diagnostico de una neoplasia neuroendocrina gastroenteropancreatica.
EA201290192A1 (ru) Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности
EA201490105A1 (ru) Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности
NZ608316A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ729773A (en) Biomarkers for disease progression in melanoma
MX2016001719A (es) Metodos y equipos para predecir el riesgo de tener una enfermedad o evento cardiovascular.
IN2014DN08537A (ru)
WO2015077382A3 (en) Combined cytology and molecular testing for early detection of esophageal adenocarcinoma
WO2016198833A3 (en) Methods for analysing a urine sample
EA202191354A1 (ru) Способы и композиции для прогнозирования ответа на терапию воспалительного заболевания кишечника
BR112016017901A2 (pt) ensaio inovador para detectar periostina humana
MX2012003168A (es) Metodos y composiciones para diagnosis y prognosis de lesion renal e insuficiencia renal.
PH12018501813A1 (en) Early detection of hepatocellular carcinoma
NZ605561A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2018085363A3 (en) Cd147 detection in diagnostic, prognostic and monitoring methods for multiple myeloma